Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A method of treating hot flashes in a patient comprising administering to the patient in need of such treatment a therapeutically effective amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt, hydrate or solvate thereof.

2. (Previously presented) A method of treating hot flashes in a patient comprising administering to the patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, or a pharmaceutically acceptable salt, hydrate or solvate thereof and a pharmaceutically acceptable vehicle.

3. (Cancelled)

4 . (Previously presented) The method of Claim 1 or Claim 2, wherein the patient is an adult and the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt, hydrate or solvate thereof is administered in a dose of 300 to 3600 mg gabapentin equivalents per day.

5. (Currently amended) The method of Claim 1[[,]] or Claim 2, ~~or Claim 3,~~ wherein the patient is a female patient.

6. (Original) The method of Claim 5, wherein the female patient is postmenopausal.

7. (Original) The method of Claim 6, wherein menopause is drug induced or surgically induced.

8. (Currently amended) The method of Claim 1[[,]] or Claim 2, ~~or Claim 3,~~ wherein the patient is a male patient.

9. (Previously presented) The method of Claim 5, wherein the hot flashes are drug-induced.

10. (Cancelled)

11. (Currently amended) The method of Claim 1[[,]] or Claim 2, ~~or Claim 3,~~ wherein the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt, hydrate or solvate thereof is administered orally.

12. (Previously presented) The method of Claim 2, wherein the pharmaceutical composition is a sustained release oral dosage form.

13. (Previously presented) The method of Claim 12, wherein the dosage form releases the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid gradually over a period of at least about 6 hours after swallowing the dosage form, thereby providing a therapeutic concentration of 1-(aminomethyl)cyclohexane acetic acid in the plasma of the patient.

14. (Original) The method of Claim 12, wherein the dosage form is an osmotic dosage form, a prodrug-releasing polymer, a prodrug-releasing lipid, a prodrug-releasing wax, tiny timed-release pills or prodrug releasing beads.

15-27. (Cancelled)

28. (Previously presented) The method of Claim 5, wherein the female patient is menopausal.

29-36. (Cancelled)

37. (Previously presented) The method of Claim 8, wherein the hot flashes are drug-induced.

38-40. (Cancelled)

41. (New) The method of claim 1 or claim 2, wherein the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt, hydrate or solvate thereof is 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid.

42. (New) The method of claim 13, wherein the 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid or a pharmaceutically acceptable salt, hydrate or solvate thereof is 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid.